In8bio, INC Form 4 insider transactions

Chief Operating Officer Kate Rochlin reports transactions involving IN8BIO, INC. warrants and common stock, including amendments to warrant terms.

IN8BIO's Chief Financial Officer, Patrick McCall, amended and exercised warrants, affecting his holdings of common stock and derivative securities.

Director Alan S. Roemer reports changes in beneficial ownership of IN8BIO, INC. stock and warrants due to amendments of warrant terms.

Director Peter C. Brandt exercised warrants and acquired shares of IN8BIO, INC. following amendments to the warrant terms.

Patrick McCall, CFO of IN8BIO, Inc., reports the acquisition of 343,000 employee stock options on February 5, 2025.

Lawrence Lamb, EVP and CSO of IN8BIO, acquired stock options for 306,750 shares on February 5, 2025.

Kate Rochlin, Chief Operating Officer of IN8BIO, INC., reports the acquisition of stock options on February 5, 2025.

William Tai-Wei Ho, President and CEO of IN8BIO, INC., acquired stock options for 912,450 shares of common stock on February 5, 2025.

Director Corinne Epperly of IN8BIO, INC. reports the acquisition of stock options on December 19, 2024.

Director Jeremy R. Graff acquires stock options in IN8BIO, INC.

Director Luba Greenwood of IN8BIO, INC. was granted stock options to purchase 39,449 shares of common stock at an exercise price of $0.24 on December 19, 2024.

Director Emily Fairbairn acquired stock options in IN8BIO, INC. on December 19, 2024.

Director Travis Whitfill acquired stock options in IN8BIO, INC. on December 19, 2024.

Director Peter C. Brandt acquired stock options for 49,490 shares of IN8BIO, Inc. at an exercise price of $0.24 on December 19, 2024.

Director Alan S. Roemer acquired stock options in IN8BIO, INC. on December 19, 2024.

Patrick McCall, CFO of IN8BIO, Inc., reports the acquisition of stock options in a transaction dated December 19, 2024.

Lawrence Lamb, EVP and CSO of IN8BIO, Inc., was granted employee stock options on December 19, 2024.

Kate Rochlin, Chief Operating Officer of IN8BIO, INC., reports the acquisition of stock options on December 19, 2024.

William Tai-Wei Ho, CEO of IN8BIO, Inc., acquired 1,188,282 employee stock options on December 19, 2024.

A recent SEC filing reveals changes in beneficial ownership of In8bio, Inc. stock following a private placement involving Bios Clinical Opportunity Fund, LP and amendments to existing warrants.

Aaron G.L. Fletcher, along with related Bios Funds, reported transactions involving In8bio, Inc. securities, including the purchase of units consisting of pre-funded warrants and Series C warrants, as well as amendments to existing Series A warrants.

Emily Fairbairn, a director of IN8BIO, INC., reports the acquisition of Series C and Pre-Funded Warrants, each representing the right to purchase 3,038,743 shares of common stock.

Kate Rochlin, Chief Operating Officer of IN8BIO, INC., reports the acquisition and disposal of common stock and warrants related to Issuer Units.

Chief Financial Officer Patrick McCall reports changes in beneficial ownership of IN8BIO, INC. securities, including the acquisition and disposal of common stock and warrants, following an amendment to existing warrants.

Director Alan S. Roemer reports acquisition of IN8BIO shares and amendment of existing warrants.

Director Peter C. Brandt reports changes in beneficial ownership of IN8BIO, Inc. securities, including warrant amendments and share acquisitions.

IN8BIO's CEO, William Tai-Wei Ho, reports acquisition of common stock and warrants, along with an amendment to existing warrants.

Kate Rochlin, Chief Operating Officer of IN8BIO, INC., received a retention award of 250,000 stock options on September 4, 2024.

IN8BIO's Chief Financial Officer, Patrick McCall, received a retention award in the form of stock options to purchase 250,000 shares of common stock on September 4, 2024.

Lawrence Lamb, EVP and CSO of IN8BIO, Inc., was granted a stock option for 250,000 shares as a retention award.